Antidyskinetic effect of JL-18, a clozapine analog, in parkinsonian monkeys

European Journal of Pharmacology

Volumn 399, Issue 2-3, 2000, Pages 183-186

  Tahar, Abdallah Hadj ^a   Bélanger, Nancy ^a   Bangassoro, Evelyne ^a   Grégoire, Laurent ^a   Bédard, Paul J ^a  

^a UNIVERSITÉ LAVAL   (Canada)

Author keywords

Dopamine D4 receptor; JL 18; L Dopa induced dyskinesia; MPTP (1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine); Parkinson's disease

Indexed keywords

BENSERAZIDE; CLOZAPINE DERIVATIVE; DOPAMINE 4 RECEPTOR; JL 18; LEVODOPA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DYSKINESIA; FEMALE; LOCOMOTION; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; BENSERAZIDE; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; FEMALE; LEVODOPA; MACACA FASCICULARIS; MOTOR ACTIVITY; PARKINSONIAN DISORDERS;

EID: 0343932824     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00310-1     Document Type: Article

References (25)

1. Aschby C.R., Wang R.Y. Pharmacological actions of the atypical antipsychotic drug clozapine: a review. Synapse. 24:1996;349-394.
2. Bennett J.P. Jr., Landow E.R., Dietrich S., Schuh L.A. Suppression of dyskinesias in advanced Parkinson's disease: moderate daily clozapine doses provide long-term dyskinesia reduction. Mov. Disord. 9:1994;409-414.
3. Blanchet P.J., Bédardfnm P.J., Matsumura M., Richard H., Filion M. Pathophysiology of levodopa-induced dyskinesia: changing concepts. Percheron G.et al. The Basal Ganglia IV. 1994;539-548 Plenum, New York.
4. Brunello N., Masotto C., Steardo L., Markstein R., Racagni G. New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology. 13:1995;177-213.
5. Chase T.N. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology. 50:1998;S17-S25.
6. Crossman A.R. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesias in Parkinson's disease: implications for future strategies in treatment. Mov. Disord. 5:1990;100-108.
7. Defagot M.C., Malchiodi E.L., Villar M.J., Antonelli M.C. Distribution of D4 dopamine receptor in rat brain with sequence-specific antibodies. Brain Res. Mol. Brain. Res. 45:1997;1-12.
8. Durif F., Vidailhet M., Assal F., Roche C., Bonnet A.M., Agid Y. Low-dose clozapine improves dyskinesias in Parkinson's disease. Neurology. 48:1997;658-662.
9. Ekesbo A., Andren P.E., Gunne L.M., Tedroff J. (-)-OSU6162 inhibits levodopa-induced dyskinesias in a monkey model of Parkinson's disease. NeuroReport. 8:1997;2567-2570.
10. Grondin R., Doan V.D., Grégoire L., Bédard P.J. D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys. Neurology. 52:1999;771-776.
11. Khan Z.U., Gutierrez A., Martin R., Penafiel A., Rivera A., De La Calle A. Differential regional and cellular distribution of dopamine D2-like receptors: an immunocytochemical study of subtype-specific antibodies in rat and human brain. Comp. Neurol. 402:1998;353-371.
12. Klawans H.L. Jr., Weiner W.J. Attempted use of haloperidol in the treatment of L-dopa induced dyskinesias. J. Neurol., Neurosurg. Psychiatry. 37:1974;427-430.
13. Lahti R.A., Evans D.L., Stratman N.C., Figur L.M. Dopamine D4 versus D2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications. Eur. J. Pharmacol. 236:1993;483-486.
14. Liegeois J.F., Bruhwyler J., Damas J., Rogister F., Masereel B., Geczy J., Delarge J. Modulation of the clozapine structure increases its selectivity for the dopamine D4 receptor. Eur J. Pharmacol. 2736:1995;R1-R3.
15. Marsden C.D. Problems with long-term levodopa therapy for Parkinson's disease. Clin. Neuropharmacol. 17:1994;S32-S44.
16. Matsumoto M., Hidaka K., Tada S., Tasaki Y., Yamaguchi T. Low levels of mRNA for dopamine D4 receptor in human cerebral cortex and striatum. J. Neurochem. 66:1996;915-919.
17. Missale C., Nash S.R., Robinson S.W., Jaber M., Caron M.G. Dopamine receptors: from structure to function. Physiol. Rev. 78:1998;189-225.
18. Mrzljak L., Bergson C., Pappy M., Huff R., Levenson R., Goldman-Rakic P.S. Localization of dopamine D4 receptors in GABAergic neurons of the primate brain. Nature. 381:1996;245-248.
19. Papa S.M., Chase T.N. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann. Neurol. 39:1996;574-578.
20. Schuh L.A., Bennett J.P. Jr. Suppression of dyskinesias in advanced Parkinson's disease: Part I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease. Neurology. 43:1993;1545-1550.
21. Tarazi F.I., Baldessarini R.J. Brain dopamine D4 receptors: basic and clinical status. Int. J. Neuropsychopharmacol. 2:1999;41-58.
22. Tarazi F.I., Campbell A., Yeghiayan S.K., Baldessarini R.J. Localization of dopamine receptor subtypes in corpus striatum and nucleus accumbens septi of rat brain: comparison of D1-, D2-, and D4-like receptors. Neuroscience. 83:1998;169-176.
23. Van Tol H.H., Bunzow J.R., Guan H.C., Sunahara R.K., Seeman P., Niznik H.B., Civelli O. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature. 350:1991;610-614.
24. Verhagen Metman L., Blanchet P.J., van den Munckhof P., Del Dotto P., Natte R., Chase T.N. A trial of dextromethorphan in parkinsonian patients with motor response complications. Mov. Disord. 13:1998;414-417.
25. Yamamoto B.K., Davy S. Dopaminergic modulation of glutamate release in striatum as measured by microdialysis. J. Neurochem. 58:1992;1736-1742.